Pages that link to "Q44966221"

The following pages link to Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression (Q44966221):

Displayed 50 items.

• Neuroinflammation and psychiatric illness (Q21245244) ‎ (← links)
• Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? (Q24631151) ‎ (← links)
• Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders (Q24632936) ‎ (← links)
• Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment (Q24633004) ‎ (← links)
• Stress as a one-armed bandit: Differential effects of stress paradigms on the morphology, neurochemistry and behavior in the rodent amygdala (Q26769043) ‎ (← links)
• A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates (Q26786354) ‎ (← links)
• Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue (Q26827833) ‎ (← links)
• The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission (Q26859198) ‎ (← links)
• Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence (Q26999061) ‎ (← links)
• Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date (Q27004490) ‎ (← links)
• Biomarkers of epileptogenesis: psychiatric comorbidities (?) (Q27015612) ‎ (← links)
• A brief history of the development of antidepressant drugs: from monoamines to glutamate (Q27028050) ‎ (← links)
• Fgfr1 inactivation in the mouse telencephalon results in impaired maturation of interneurons expressing parvalbumin (Q27316919) ‎ (← links)
• Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons (Q27319478) ‎ (← links)
• Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466 (Q28236198) ‎ (← links)
• GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response (Q28241963) ‎ (← links)
• Dynamic changes in extracellular release of GABA and glutamate in the lateral septum during social play behavior in juvenile rats: Implications for sex-specific regulation of social play behavior (Q28266736) ‎ (← links)
• Inflammatory biomarkers and depression (Q28288750) ‎ (← links)
• Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice (Q28485938) ‎ (← links)
• GABA concentration in posterior cingulate cortex predicts putamen response during resting state fMRI (Q28542754) ‎ (← links)
• Revisiting the monoamine hypothesis of depression: a new perspective (Q28660308) ‎ (← links)
• Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy (Q30249189) ‎ (← links)
• Sex chromosome complement regulates expression of mood-related genes. (Q30409984) ‎ (← links)
• GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism (Q30421260) ‎ (← links)
• Effects of chronic stress on prefrontal cortex transcriptome in mice displaying different genetic backgrounds (Q30455519) ‎ (← links)
• Advances in the treatment of anxiety: targeting glutamate (Q30457479) ‎ (← links)
• The GABAergic deficit hypothesis of major depressive disorder. (Q30464954) ‎ (← links)
• gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression (Q30496339) ‎ (← links)
• Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression (Q30572014) ‎ (← links)
• Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder (Q30711088) ‎ (← links)
• Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac (Q30818437) ‎ (← links)
• Molecular imaging for depressive disorders (Q30821361) ‎ (← links)
• Brain proton magnetic resonance spectroscopy of alcohol use disorders (Q30859378) ‎ (← links)
• Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants (Q30887852) ‎ (← links)
• Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift (Q30906677) ‎ (← links)
• In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature (Q30927398) ‎ (← links)
• A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. (Q30987882) ‎ (← links)
• Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder (Q31032734) ‎ (← links)
• The biochemistry of dysfunctional emotions: proton MR spectroscopic findings in major depressive disorder (Q31063942) ‎ (← links)
• Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of (1) H-MRS studies (Q31090438) ‎ (← links)
• Fully automated macromolecule suppressed single voxel glutamate spectroscopy (FAMOUS SVGS). (Q31117451) ‎ (← links)
• Beyond monoamines: glutamatergic function in mood disorders (Q33231128) ‎ (← links)
• Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). (Q33384845) ‎ (← links)
• Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder (Q33389974) ‎ (← links)
• Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders (Q33429548) ‎ (← links)
• Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression (Q33492323) ‎ (← links)
• Impact of frequency drift on gamma-aminobutyric acid-edited MR spectroscopy (Q33594723) ‎ (← links)
• Antidepressant interactions with the NMDA NR1-1b subunit (Q33602533) ‎ (← links)
• The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. (Q33624724) ‎ (← links)
• Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies (Q33664090) ‎ (← links)